[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"extranodal-nk-t-cell-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:extranodal-nk-t-cell-lymphoma":47},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100633344","phase-1-combination-of-mitoxantrone-liposome-and-etoposide-dexamethasone-pegaspargase-and-golidocitinib-mepl-g-in-the-treatment-of-nkt-cell-lymphoma-associated-hemophagocytic-lymphohistiocytosis-nktcl-hlh-100633344",false,"NCT07525466","Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK\u002FT-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)","Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK\u002FT-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH): a Prospective, Multi-center, Single Arm, Phase Ib\u002FII Clinical Trial","Inclusion Criteria:\n\n* Histologically confirmed extranodal NK\u002FT-cell lymphoma.\n* Meeting the HLH-2004 diagnostic criteria (≥ 5 criteria).\n* Age ≥ 18 years, regardless of gender.\n* Negative HIV antigen or antibody.\n* Left ventricular ejection fraction (LVEF) ≥ 50% on cardiac echocardiography.\n* No active visceral bleeding (e.g., gastrointestinal, pulmonary, cerebral).\n* No uncontrolled infection (e.g., pulmonary infection, intestinal infection).\n* Negative HCV antibody; or positive HCV antibody with negative HCV RNA.\n* Negative HBsAg and negative HBcAb. If either is positive, peripheral blood HBV DNA load must be \\\u003C 1×10³ copies\u002FmL to be eligible.\n* Signed written informed consent and ability to understand and comply with all study requirements.\n\nExclusion Criteria:\n\n* New York Heart Association (NYHA) cardiac function class ≥ II;\n* Female patients who are pregnant or breastfeeding;\n* Known hypersensitivity to any of the study drugs;\n* Presence of other concurrent malignancies (except non-melanoma skin cancer);\n* Concurrent central nervous system lymphoma infiltration;\n* Severe psychiatric disorders or inability to comply with follow-up;\n* Severe renal dysfunction (glomerular filtration rate \\\u003C 15 mL\u002Fmin);\n* Severe liver cirrhosis (MELD score \\> 20);\n* History of acute or chronic pancreatitis;\n* Simultaneous participation in another clinical trial.","ALL","18 Years",{"count":19,"type":20},25,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","Extranodal NK\u002FT-cell lymphoma (NKTCL) is an aggressive EBV-associated lymphoma with poor prognosis, highly prevalent in China. Early-stage NKTCL achieves favorable long-term survival, while advanced disease shows dismal outcomes with no standard therapy. Notably, 10%-20% of patients develop secondary hemophagocytic lymphohistiocytosis (NKTCL-HLH), a life-threatening complication with median survival \\\u003C2 months and mortality over 90%. Current treatments fail to simultaneously control lymphoma and hyperinflammation, with poor tolerance and high resistance.\n\nThe JAK\u002FSTAT pathway drives EBV-induced inflammation and tumor progression. Golidocitinib, a selective JAK1 inhibitor, demonstrates potent anti-NKTCL activity and rapid inflammation control. Liposomal mitoxantrone offers targeted efficacy with lower toxicity, while etoposide, methylprednisolone, and pegaspargase provide synergistic anti-tumor and anti-HLH effects.\n\nThis study proposes the novel MEPL-G regimen (liposomal mitoxantrone, etoposide, methylprednisolone, pegaspargase, golidocitinib) for NKTCL-HLH. By targeting both HLH and NKTCL, this combination aims to achieve rapid disease control, improve tolerance, and prolong survival, addressing the unmet critical clinical need for this high-risk population.",[27,28],"Extranodal NK T Cell Lymphoma","Hemophagocytic Lymphohistiocytosis (HLH)",[30,31,32,33,34],"extranodal NK\u002FT-cell lymphoma","hemophagocytic lymphohistiocytosis","Mitoxantrone Liposome","Golidocitinib","JAK1","RECRUITING","2026-04-07",{"date":38,"type":39},"2026-04-13","ACTUAL",{"date":41,"type":39},"2026-04-01",{"date":43,"type":20},"2028-09-30",{"name":45,"class":46},"Beijing Tongren Hospital","OTHER","Extranodal NK-T-Cell Lymphoma"]